New England Biolabs EM-seq v2
New England Biolabs has launched EM-seq v2, an updated enzymatic methylation profiling assay kit that provides an alternative to bisulfite sequencing for the identification of 5mC and 5hmC. According to the company, the newly updated kit has a wider input range of 100 pg to 200 ng, and a faster, more streamlined workflow as compared to the original EM-seq kit. It also provides higher-quality data with more GC coverage and detection of more CpGs with fewer sequence reads, NEB said.
BioSkryb ResolveSeq MRD
BioSkryb has launched ResolveSeq MRD, a service for classification and characterization of the minimum residual disease cells in hematologic malignancies. ResolveSeq MRD pairs single-cell genome and transcriptome characterization and integrates with flow cytometry protocols. It provides clonal evolution mapping and risk stratification for each subclone, the company said.
23andMe Discover23
23andMe launched the Discover23 platform, which evaluates associations of over 172 million genetic variants across 4.7 billion phenotypic data points from genome-wide association studies conducted on over 1,000 disease and condition cohorts. Biopharma customers will have access to summarized results of analyses conducted using de-identified data to help identify novel disease biology, discover potential new drug targets, and add genetic evidence to diverse research programs.
Parse Biosciences Evercode WT Mega
Parse Biosciences has expanded its Evercode WT Mega single-cell sequencing kit. Researchers can now analyze up to 1 million cells across 384 samples in a single run, up from 96 samples.
NashBio Therapeutic-Area Data Collections and Secure Research Platform
Nashville Biosciences (NashBio) is launching two new products designed to provide life science researchers, pharmaceutical companies, and biotech innovators with access to de-identified electronic health record (EHR) and linked genomic data for precision medicine research.
First, the company has launched therapeutic-area data collections, which are expertly curated, specialty-aligned datasets designed to make it easier to use complex clinical data features in high-priority therapeutic areas. By aligning high-quality EHR and genomic data with specific therapeutic needs, scientists can find the best datasets for their research needs to bring innovative drugs and diagnostics to market faster, NashBio said.
In addition, in the spring of 2025, the company will launch its secure research platform, a scalable, cloud-based, data-as-a-service subscription platform that enables researchers to rapidly identify and analyze patient cohorts using disease-specific phenotypes, longitudinal clinical data, and genomic insights "on their own terms and timelines," the company said.
For more recently launched products and services, please visit the New Products page on our website.